

## Curriculum Vitae

**Bastian Opitz** Professor, Dr. med.  
d.o.b. February 13th, 1976, in Berlin, Germany

### University Education

2009 Habilitation Experimental Medicine, Charité Universitätsmedizin Berlin  
2003 Doctorate Medicine, Charité Universitätsmedizin Berlin (*summa cum laude*)  
1995–2002 Studies of Medicine, Humboldt-University, Berlin

### Scientific Career

Since 2025 Professor of Infection Immunology (W3, tenured), Charité  
Since 2024 Elected Deputy Speaker of the study group “Infection Immunology” of the German Society of Immunology (DGfI) and the German Society of Hygiene and Microbiology (DGHM)  
Since 2023 Faculty, MD/PhD Graduate Program “Re-Thinking Health”, Charité, Berlin, Germany  
2020-2022 PI, BMBF-funded research network MAPVAP  
Since 2018 Editorial Board member - *Med Microbiol Immunol*.  
Since 2014 Editorial Board member - *Am J Respir Cell Mol Biol*.  
2010-2023 PI, collaborative research center / transregio (SFB-TR84), since 2018 member of the executive board  
2015-2019 PI, DFG-funded priority program (SPP1580)  
2010-2015 PI, DFG-funded international graduate school GRK1673  
2010-2015 Training in Medical Microbiology, Charité – Universitätsmedizin Berlin and Labor Berlin, Board Certificate “Medical Microbiology, Virology and Infection epidemiology”  
2010-2025 Professor of Lung Infections and Immunology (W2, tenured), Charité  
Since 2009 Faculty, PhD Program “Interdisciplinary Center of Infection Biology and Immunity” (ZIBI), Charité, Berlin, Germany  
Since 2008 PI of various individual DFG research grants (“Sachbeihilfen”): OP 86/17-1, OP86/13-1, OP86/12-1, OP86/7-2, OP86/7-1, OP86/5-1  
2008 Visiting scientist, Yale University School of Medicine, Section of Microbial Pathogenesis, Prof. Craig Roy; funded by the Boehringer Ingelheim Foundation  
Since 2006 Scientific Group Leader at the Department of Internal Medicine/Infectious Diseases and Pulmonary Medicine, Charité – Universitätsmedizin Berlin  
2004-2006 Postdoc at the Department of Internal Medicine/Infectious Diseases and Pulmonary Medicine, Charité – Universitätsmedizin Berlin  
2003–2004 „Arzt im Praktikum, Department of Internal Medicine/Infectious Diseases and Pulmonary Medicine, Charité – Universitätsmedizin Berlin

### Awards and Stipends

2024 Paper of the Month”, German Society of Hygiene and Microbiology (DGHM)  
2018 Wolfgang-Stille prize of the Paul-Ehrlich-Society (PEG)  
2016 “Paper of the Month”, German Society of Hygiene and Microbiology (DGHM)  
2009 Fritz-und-Ursula-Melchers prize of the German Society of Immunology (DGfI)  
2008 Stipend by the Boehringer Ingelheim Foundation  
2006 Research stipend, German Respiratory Society (DGP)

### Citation Record

Total citations: 6,193; h-index: 43 (Web of Science February 2<sup>nd</sup>, 2026)

## Top-10 selected Publications

Fiocca Vernengo F, Röwekamp I, Boillot L, Caesar S, Dörner PJ, Tarnowski B, Gutbier B, Nouailles G, Fatykhova D, Hellwig K, Witzernath M, Hocke AC, Klatt AB, **Opitz B**. Diabetes impairs IFN $\gamma$ -dependent antibacterial defense in the lungs. **Mucosal Immunol**. 2025 Apr;18(2):431-440.

Essex M\*, Millet Pascual-Leone B\*, Löber U, Kuhring M, Zhang B, Brüning U, Fritsche-Guenther R, Krzanowski M, Fiocca Vernengo F, Brumhard S, Röwekamp I, Anna Bielecka A, Lesker TR, Wyler E, Landthaler M, Mantei A, Meisel C, Caesar S, Thibeault C, Corman VM, Marko L, Suttorp N, Strowig T, Kurth F, Sander LE, Li Y, Kirwan JA\*, Forslund SK\*, **Opitz B\***. Gut microbiota dysbiosis is associated with altered tryptophan metabolism and dysregulated inflammatory response in severe COVID-19. **npj Biofilms and Microbioms**. 2024;10(1):66.

Röwekamp I\*, Maschirow L\*, Rabes A\*, Fiocca Vernengo F, Hamann L, Heinz GA, Mashreghi MF, Caesar S, Milek M, Fagundes Fonseca AC, Wienhold SM, Nouailles G, Yao L, Mousavi S, Bruder D, Boehme JD, Puzianowska-Kuznicka M, Beule D, Witzernath M; CAPNETZ Study Group; Löhning M, Klose CSN, Heimesaat MM, Diefenbach A, **Opitz B**. IL-33 controls IL-22-dependent antibacterial defense by modulating the microbiota. **Proc Natl Acad Sci U S A**. 2024; 121(22):e2310864121.

Dörner PJ, Anandakumar H, Röwekamp I, Fiocca Vernengo F, Millet Pascual-Leone B, Krzanowski M, Sellmaier J, Brüning U, Fritsche-Guenther R, Pfannkuch L, Kurth F, Milek M, Igbokwe V, Löber U, Gutbier B, Holstein M, Heinz GA, Mashreghi MF, Schulte LN, Klatt AB, Caesar S, Wienhold SM, Offermanns S, Mack M, Witzernath M, Jordan S, Beule D, Kirwan JA, Forslund SK, Wilck N, Bartolomaeus H, Heimesaat MM, **Opitz B**. Clinically used broad-spectrum antibiotics compromise inflammatory monocyte-dependent antibacterial defense in the lung. **Nat Commun**. 2024; 15(1):2788.

Thibeault C, Suttorp N, **Opitz B**. The microbiota in pneumonia: from protection to predisposition. **Sci Transl Med**. 2021;13

Robak O, Heimesaat MM, Kruglov A, Prepens S, Gutbier B, Reppe K, Hochrein H, Suter M, Kirschning CJ, Schneider P, Witzernath M, Bereswill S, Steinhoff U, Suttorp N, Sander LE, Chaput C\*, **Opitz B\***. Antibiotic treatment-induced secondary IgA-deficiency enhances susceptibility to *Pseudomonas aeruginosa* pneumonia. **J Clin Invest**. 2018;28:3535-3545.

Ruiz-Moreno JS, Hamann L, Shah JA, Verbon A, Mockenhaupt FP, Puzianowska-Kuznicka M, Naujoks J, Sander LE, Witzernath M, Cambier JC, Suttorp N, Schumann RR, Jin L, Hawn TR, **Opitz B**, CAPNETZ Study Group. A common hypomorphic STING variant affects cGAS-dependent antibacterial defense and is associated with susceptibility to Legionnaires' disease in humans. **PLOS Pathogens**. 2018;14:e1006829.

Naujoks N, Tabeling C, Dill BD, Hoffmann C, Brown AS, Kunze M, Kempa S, Peter A, Mollenkopf HJ, Dorhoi A, Kershaw O, Gruber AD, Sander LE, Witzernath M, Herold S, Nehrlich A, Hocke AC, van Driel I, Suttorp N, Bedoui B, Hilbi H, Trost M, **Opitz B**. IFNs modify the proteome of Legionella-containing vacuoles and restrict infection via IRG1-derived itaconic acid. **PLoS Pathogens**. 2016;12:e1005408.

**Opitz B**, van Laak V, Eitel J, Suttorp N. Innate immune recognition in infectious and non-infectious diseases of the lung. **Am J Respir Crit Care Med**. 2010;181:1294-309.

**Opitz B**, Förster S, Hocke AC, Maass M, Schmeck B, Hippenstiel S, Suttorp N, Krüll M. Nod1 mediated endothelial cell activation by *C. pneumoniae*. **Circ. Res**. 2005;96:319-26.